Stryker Corporation (LON: 0R2S)
London
· Delayed Price · Currency is GBP · Price in USD
365.66
+9.65 (2.71%)
Dec 23, 2024, 6:43 PM BST
Stryker Revenue
Stryker had revenue of $5.49B USD in the quarter ending September 29, 2024, with 11.92% growth. This brings the company's revenue in the last twelve months to $21.97B, up 10.51% year-over-year. In the year 2023, Stryker had annual revenue of $20.50B with 11.11% growth.
Revenue (ttm)
$21.97B
Revenue Growth
+10.51%
P/S Ratio
n/a
Revenue / Employee
$422.58K
Employees
52,000
Market Cap
110.55B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 30, 2023 | 20.50B | 2.05B | 11.11% |
Dec 30, 2022 | 18.45B | 1.34B | 7.84% |
Dec 30, 2021 | 17.11B | 2.76B | 19.21% |
Dec 30, 2020 | 14.35B | -533.00M | -3.58% |
Dec 30, 2019 | 14.88B | 1.28B | 9.43% |
Dec 30, 2018 | Pro | Pro | Pro |
Dec 30, 2017 | Pro | Pro | Pro |
Dec 30, 2016 | Pro | Pro | Pro |
Dec 30, 2015 | Pro | Pro | Pro |
Dec 30, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionStryker News
- 7 days ago - How Is The Market Feeling About Stryker? - Benzinga
- 7 days ago - Here's How Much You Would Have Made Owning Stryker Stock In The Last 10 Years - Benzinga
- 13 days ago - Stryker raises dividend by 5% to $0.84 - Seeking Alpha
- 13 days ago - Stryker Corp (SYK) Announces 5% Increase in Quarterly Dividend - GuruFocus
- 13 days ago - Stryker declares an $0.84 per share quarterly dividend - GlobeNewsWire
- 20 days ago - Morgan Stanley bullish on medtech in 2025, upgrades 5 stocks - Seeking Alpha
- 20 days ago - Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos - Benzinga
- 20 days ago - Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos - Benzinga